Literature DB >> 23430928

The ketogenic diet is well tolerated and can be effective in patients with argininosuccinate lyase deficiency and refractory epilepsy.

Rosanne Peuscher1, Monique E Dijsselhof, Nico G Abeling, Margreet Van Rijn, Francjan J Van Spronsen, Annet M Bosch.   

Abstract

Argininosuccinate lyase (ASL) deficiency (MIM 608310, McKusick 207900) is a rare disorder of the urea cycle, which leads to a deficiency of arginine and hyperammonemia. Epilepsy is a frequent complication of this disorder. A ketogenic diet (KD) can be a very effective therapy for refractory epilepsy, and it has been widely used in children. Until now, no experiences with the KD in patients with urea cycle defects have been reported.We present two cases of patients with ASL deficiency and refractory epilepsy who were treated with a KD. In both patients, the KD was initiated during a hospital admission and the fat percentage of the diet was increased to above 90% in five equal steps. In patient 1, during the KD the protein intake was continued as before, and in patient 2 the natural protein was increased with 0,2 g/kg/day while the protein from the amino acid supplement (UCD-2(®), Milupa) was decreased with 0,3 g/kg/day. During and after the introduction of the KD, all biochemical parameters reflecting urea cycle function and ammonia levels were stable in both patients and no signs of derangement were detected. On the KD, patient 1 demonstrated a reduction in seizure frequency of >50%, and an increase in well-being. In patient 2, no effects of the KD on the seizure frequency were noted and after 6 months the KD was discontinued.Concluding, the KD does not cause metabolic derangement, is well tolerated, and can be effective in patients with ASL deficiency who are treated with a protein restriction.

Entities:  

Year:  2011        PMID: 23430928      PMCID: PMC3509918          DOI: 10.1007/8904_2011_115

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  8 in total

1.  Epilepsy and argininosuccinic aciduria.

Authors:  D Grioni; F Furlan; C Corbetta; C Barboni; A Lastrico; G M Marzocchi; M Contri; A Gamba; P Vizziello; R Parini
Journal:  Neuropediatrics       Date:  2011-07-08       Impact factor: 1.947

2.  The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial.

Authors:  Elizabeth G Neal; Hannah Chaffe; Ruby H Schwartz; Margaret S Lawson; Nicole Edwards; Geogianna Fitzsimmons; Andrea Whitney; J Helen Cross
Journal:  Lancet Neurol       Date:  2008-05-02       Impact factor: 44.182

3.  Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group.

Authors:  Eric H Kossoff; Beth A Zupec-Kania; Per E Amark; Karen R Ballaban-Gil; A G Christina Bergqvist; Robyn Blackford; Jeffrey R Buchhalter; Roberto H Caraballo; J Helen Cross; Maria G Dahlin; Elizabeth J Donner; Joerg Klepper; Rana S Jehle; Heung Dong Kim; Y M Christiana Liu; Judy Nation; Douglas R Nordli; Heidi H Pfeifer; Jong M Rho; Carl E Stafstrom; Elizabeth A Thiele; Zahava Turner; Elaine C Wirrell; James W Wheless; Pierangelo Veggiotti; Eileen P G Vining
Journal:  Epilepsia       Date:  2008-09-23       Impact factor: 5.864

Review 4.  Energy metabolism as part of the anticonvulsant mechanism of the ketogenic diet.

Authors:  Kristopher Bough
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

Review 5.  Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet.

Authors:  Jörg Klepper
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

6.  Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening.

Authors:  C Ficicioglu; R Mandell; V E Shih
Journal:  Mol Genet Metab       Date:  2009-06-25       Impact factor: 4.797

7.  Ketogenic diet for the treatment of catastrophic epileptic encephalopathies in childhood.

Authors:  Giangennaro Coppola; Alberto Verrotti; Edoardo Ammendola; Francesca Felicia Operto; Rita Della Corte; Giuseppe Signoriello; Antonio Pascotto
Journal:  Eur J Paediatr Neurol       Date:  2009-07-25       Impact factor: 3.140

Review 8.  Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond.

Authors:  Ayelet Erez; Sandesh C Sreenath Nagamani; Brendan Lee
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-02-10       Impact factor: 3.908

  8 in total
  4 in total

Review 1.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

2.  Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease.

Authors:  Katrina J Llewellyn; Angèle Nalbandian; Kwang-Mook Jung; Christopher Nguyen; Agnesa Avanesian; Tahseen Mozaffar; Daniele Piomelli; Virginia E Kimonis
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

3.  A Fine Balance of Dietary Lipids Improves Pathology of a Murine Model of VCP-Associated Multisystem Proteinopathy.

Authors:  Katrina J Llewellyn; Naomi Walker; Christopher Nguyen; Baichang Tan; Lbachir BenMohamed; Virginia E Kimonis; Angèle Nalbandian
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

4.  Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: A clinical prospective study.

Authors:  Qiong Wu; Hua Wang; Yu Ying Fan; Jun Mei Zhang; Xue Yan Liu; Xiu Ying Fang; Feng Hua Yang; Qing Jun Cao; Ying Qi
Journal:  Brain Behav       Date:  2018-04-18       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.